Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
- John P H Wilding, G. Charpentier, G. Meininger
- MedicineInternational journal of clinical practice
- 13 October 2013
This randomised, double‐blind, placebo‐controlled, Phase 3 study evaluated the efficacy and safety of canagliflozin as an add‐on to metformin plus sulphonylurea in patients with T2DM.
An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: the A1chieve study.
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L…
Compared withiGlar, a substantially higher proportion of iGlarLixi-treated patients achieved glycemic targets with a beneficial effect on body weight, no additional risk of hypoglycemia, and low levels of gastrointestinal adverse effects in inadequately controlled, basal insulin-treated, long-standing type 2 diabetes.
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled…
The dipeptidyl peptidase‐4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus
- G. Garcia-Soria, G. González-Gálvez, H. Guler
- Medicine, ChemistryDiabetes, obesity & metabolism
- 1 April 2008
Aim: To determine the efficacy and tolerability of PHX1149, a novel dipeptidyl peptidase‐4 (DPP4) inhibitor, in patients with type 2 diabetes.
Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials.
Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The…
VASCULAR COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES: PREVALENCE AND COMORBIDITIES IN 6 COUNTRIES OF LATIN AMERICA (A COHORT OF THE DISCOVER STUDY PROGRAM).
- C. Chen-Ku, G. González-Gálvez, M. de sa Pereira
- MedicineEndocrine practice : official journal of the…
- 6 June 2019
It is shown that patients with Type 2 diabetes in Latin America are not reaching their glucose, lipids, blood pressure and weight targets, and the need for more aggressive risk factor screening as well as treatment is highlighted.